Gland Pharma Gets US FDA Nod for Generic Sugammadex Injection
Source: ET Real Estate
Arth Insight · What this means for your wallet
- **Investment Potential:** If you own Gland Pharma shares, their value might increase due to US market expansion.
- **Mutual Fund Impact:** Your pharma-focused mutual funds or ETFs could see a positive bump if they hold Gland Pharma.
- **No Direct Consumer Benefit:** This US approval does not immediately lower your personal surgery or medicine costs in India.
Gland Pharma has received US FDA approval for its generic version of sugammadex injection, a drug used to reverse muscle relaxants during surgery. This approval marks a significant step for the company in the US market.
- ▸Gland Pharma's generic sugammadex injection approved by USFDA.
- ▸The drug reverses muscle relaxant effects used in surgery.
- ▸The generic is bioequivalent to Merck's BRIDION injection.
- ▸This approval could boost Gland Pharma's US market presence.
- ✓Gland Pharma's generic sugammadex injection approved by USFDA.
- ✓The drug reverses muscle relaxant effects used in surgery.
- ✓The generic is bioequivalent to Merck's BRIDION injection.
- ✓This approval could boost Gland Pharma's US market presence.
Gland Pharma has secured approval from the United States Food and Drug Administration (USFDA) for its generic sugammadex injection. This drug plays a crucial role in surgical procedures by reversing the effects of muscle relaxants administered to patients.
The USFDA approval covers two specific strengths of the single-dose vial product. The newly approved generic injection is bioequivalent to Merck's original BRIDION injection, indicating comparable efficacy and safety. The market for sugammadex injection in the US has shown significant sales in the past year, suggesting a substantial demand for such pharmaceutical products.
This development is a positive step for Gland Pharma, potentially expanding its product portfolio and market reach in the United States. The company's ability to bring generic versions of critical drugs to market highlights its manufacturing capabilities and its role in making healthcare more accessible.
This report is for informational purposes only and does not constitute investment advice.
Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.
Frequently Asked Questions
What is sugammadex injection used for?
Sugammadex injection is used to reverse the effects of muscle relaxant drugs that are administered during surgical procedures.
Which company's product is Gland Pharma's generic equivalent to?
Gland Pharma's generic sugammadex injection is bioequivalent to Merck's BRIDION injection.
What does USFDA approval signify?
USFDA approval means the drug has met the stringent safety and efficacy standards set by the United States Food and Drug Administration, allowing it to be marketed and sold in the US.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about real-estate
Dr Reddy's Pivots to Generic Semaglutide, Biosimilars for Future Growth
Dr Reddy's Laboratories is strategically focusing on the relaunch of generic semaglutide and expanding its biosimilars portfolio to drive future growth. This comes as the company navigates mixed results, with domestic formulations business growing but North American Revlimid sales declining in the September quarter.
Aayush Wellness Launches Calcium & Vitamin D Tablets, Enters ₹1.35 Lakh Crore Bone Health Market
Aayush Wellness Limited has launched new calcium and vitamin D tablets, marking its entry into India's significant bone and joint health segment. This expansion reflects the growing consumer demand for preventive healthcare and nutritional supplements designed to support musculoskeletal health.
NITI Aayog Eyes Policy Reforms to Boost India's Medical Device Manufacturing
NITI Aayog is actively exploring new policy measures to enhance India's domestic manufacturing capabilities for medical and dental devices. The initiative addresses significant hurdles like complex regulations and cost disadvantages faced by local producers. The goal is to strengthen the 'Make in India' drive within the crucial healthcare sector.
Related Stories
Dr Reddy's Pivots to Generic Semaglutide, Biosimilars for Future Growth
Dr Reddy's Laboratories is strategically focusing on the relaunch of generic semaglutide and expanding its biosimilars portfolio to drive future growth. This comes as the company navigates mixed results, with domestic formulations business growing but North American Revlimid sales declining in the September quarter.
Aayush Wellness Launches Calcium & Vitamin D Tablets, Enters ₹1.35 Lakh Crore Bone Health Market
Aayush Wellness Limited has launched new calcium and vitamin D tablets, marking its entry into India's significant bone and joint health segment. This expansion reflects the growing consumer demand for preventive healthcare and nutritional supplements designed to support musculoskeletal health.
NITI Aayog Eyes Policy Reforms to Boost India's Medical Device Manufacturing
NITI Aayog is actively exploring new policy measures to enhance India's domestic manufacturing capabilities for medical and dental devices. The initiative addresses significant hurdles like complex regulations and cost disadvantages faced by local producers. The goal is to strengthen the 'Make in India' drive within the crucial healthcare sector.
Health Ministry Ordered to Probe Coronary Stent Safety Concerns by Cabinet Secretariat
The Cabinet Secretariat has directed the Union Health Ministry to investigate safety concerns surrounding coronary stents. This action follows concerns raised by Rajya Sabha member Ajeet Madhavrao Gopchade, highlighting issues with models withdrawn in Sri Lanka and calling for a stronger regulatory framework in India.